MHP
AST

Manatuck Hill Partners’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Manatuck Hill Partners’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-100,567
Closed -$61K – 116
2016
Q2 		$61K Buy
+100,567
New +$364K 0.03% 86

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Manatuck Hill Partners's AST Position: Q3 2016 in Review

Manatuck Hill Partners sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q3 2016, closing a stake of 100,567 shares — an estimated $61K sold.

Manatuck Hill Partners first reported a position in AST in Q2 2016 and held it in 1 quarter. The position peaked at $61K in Q2 2016. 64 funds tracked by Wall St. Rank hold AST as of Q3 2016.

  • Manatuck Hill Partners reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q3 2016 after selling out during the quarter.
  • Manatuck Hill Partners sold 100,567 Asterias Biotherapeutics Inc. Series A shares in Q3 2016, an estimated $61K.
  • Manatuck Hill Partners first reported a position in Asterias Biotherapeutics Inc. Series A in Q2 2016 and held it in 1 quarter.
  • Manatuck Hill Partners's Asterias Biotherapeutics Inc. Series A position peaked at $61K in Q2 2016.
  • 64 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q3 2016.

Based on Manatuck Hill Partners's 13F filing for Q3 2016, filed 14 Nov 2016.